Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab

Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab

Abstract Background Previous studies have suggested that elevated neutrophil-to-lymphocyte ratio (NLR) is prognostic for worse outcomes in patients with a variety of solid cancers, including those treated with immune checkpoint inhibitors. Methods This was a retrospective analysis of 97 consecutive...

Full description

Bibliographic Details
Main Authors: Mariaelena Capone, Diana Giannarelli, Domenico Mallardo, Gabriele Madonna, Lucia Festino, Antonio Maria Grimaldi, Vito Vanella, Ester Simeone, Miriam Paone, Giuseppe Palmieri, Ernesta Cavalcanti, Corrado Caracò, Paolo Antonio Ascierto
Format: Article
Language:English
Published: BMJ Publishing Group 2018-07-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
PD-1 inhibitor
Nivolumab
Biomarkers
Neutrophil-to-lymphocyte ratio
Online Access:http://link.springer.com/article/10.1186/s40425-018-0383-1

Internet

http://link.springer.com/article/10.1186/s40425-018-0383-1

Similar Items